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The United Kingdom (UK) is in the third season of 
introducing universal paediatric influenza vaccina-
tion with a quadrivalent live attenuated influenza 
vaccine (LAIV). The 2015/16 season in the UK was ini-
tially dominated by influenza A(H1N1)pdm09 and then 
influenza of B/Victoria lineage, not contained in that 
season’s adult trivalent inactivated influenza vaccine 
(IIV). Overall adjusted end-of-season vaccine effec-
tiveness (VE) was 52.4% (95% confidence interval (CI): 
41.0–61.6) against influenza-confirmed primary care 
consultation, 54.5% (95% CI: 41.6–64.5) against influ-
enza A(H1N1)pdm09 and 54.2% (95% CI: 33.1–68.6) 
against influenza B. In 2–17 year-olds, adjusted VE 
for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any 
influenza, 81.4% (95% CI: 39.6–94.3) against influenza 
B and 41.5% (95% CI: −8.5 to 68.5) against influenza 
A(H1N1)pdm09. These estimates demonstrate moder-
ate to good levels of protection, particularly against 
influenza B in children, but relatively less against 
influenza A(H1N1)pdm09. Despite lineage mismatch 
in the trivalent IIV, adults younger than 65 years were 
still protected against influenza B. These results pro-
vide reassurance for the UK to continue its influenza 
immunisation programme planned for 2016/17.
Introduction
The United Kingdom (UK) has had a long-standing 
selective inactivated influenza vaccination programme 
targeted at individuals at higher risk of severe disease 
such as the elderly, those with an underlying clinical 
risk condition and pregnant women. Following recom-
mendations from the Joint Committee of Vaccination 
and Immunisation (JCVI) in 2012, the decision was 
taken for a phased introduction of a newly licensed live 
attenuated influenza vaccine (LAIV), ultimately offered 
LAIV in each season to all healthy children aged two to 
16 years [1]. 2015/16 is the third season of the introduc-
tion of this new influenza vaccination programme; all 
healthy children aged two to four years and in school 
years 1 and 2 were offered a single dose of LAIV [2]. 
In Northern Ireland and Scotland and in selected pilot 
areas in England, all other older children of primary 
school age were also offered LAIV in 2015/16. Children 
aged two to 17 years in a clinical risk group were also 
offered LAIV, while children with a risk factor, in whom 
LAIV is contraindicated, were offered quadrivalent 
inactivated influenza vaccine (IIV). All children in a 
clinical risk group aged six to 23 months were offered 
IIV. The United States Centers for Disease Control and 
Prevention (US CDC) recently reported the observation 
that LAIV did not provide protection in children against 
circulating influenza strains in North America in the 
2015/16 season [3]. This raised a question about the 
effectiveness of LAIV in children in the UK.
In the UK, the 2015/16 season started late, peaking in 
week 11 of 2016, with circulation initially dominated by 
influenza A(H1N1)pdm09 viruses. Impact mainly fell on 
younger adults resulting in large numbers of hospitali-
sations and admissions to intensive care units (ICU) [4]. 
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Genetically, the haemagglutinin (HA) genes of A(H1N1)
pdm09 viruses all belonged in subgroup 6B, the pre-
dominant clade circulating in the 2014/15 season. The 
later stages of the 2015/16 season were dominated by 
influenza B circulation, with the majority of viruses 
antigenically similar to B/Brisbane/60/2008, the influ-
enza B/Victoria lineage component included in the 
2015/16 northern hemisphere quadrivalent vaccine but 
not in the trivalent vaccine [4]. This raised questions 
about the protection provided by the 2015/16 trivalent 
vaccine, the main influenza vaccine offered to adults, 
and about the potential added value of switching to 
quadrivalent vaccine as the main vaccine of choice.
Following the mid-2015/16 season report of influenza 
vaccination effectiveness (VE) [5], this article presents 
the end-of-season estimates of influenza VE using well 
established systems across the four countries of the UK 
[6,7]. The aims of the investigation were to measure VE 
against laboratory-confirmed influenza by type, sub-
type and clade/lineage, and to determine the effective-
ness of the vaccine in children two to 17 years of age 
according to type of vaccine, particularly in relation to 
LAIV, but also IIV. In addition, we estimated the effec-
tiveness of both LAIV and IIV in children two to 17 years 
of age over the three seasons since the UK introduced 
the LAIV programme.
Methods
Study population and period
The test-negative case–control (TNCC) design was 
used to estimate VE. The study was undertaken in 
five sentinel general practice surveillance networks 
across the UK, details of which have been outlined 
previously [7]. The surveillance schemes were: Royal 
College of General Practitioners (RCGP), Research and 
Surveillance Centre (RSC), Specialist Microbiology 
Network (SMN) England and Wales, Northern Ireland 
and Scotland.
The main study took place from 1 October 2015 until 1 
May 2016. The study population were patients present-
ing to their general practitioner (GP) during the study 
period with an acute influenza-like illness (ILI), who 
the physician consented verbally to be swabbed dur-
ing the consultation. A patient with ILI was defined as 
an individual presenting in primary care with an acute 
respiratory illness with physician-diagnosed fever or 
complaint of feverishness. GPs were asked to swab a 
random sample of cases up to a total of 10 per week 
in any one practice. Cases were patients who tested 
positive for influenza A or B virus by real-time PCR. 
Controls were patients with the same symptoms who 
tested negative for influenza A and B. Further details of 
the laboratory methods are provided below.
During the consultation, the GP completed a stand-
ard questionnaire. It collected demographic, clinical 
and epidemiological information from patients includ-
ing potential confounders such as sex, date of birth, 
underlying clinical risk factors, date of onset of ILI, 
date of sample collection (recommended within seven 
days of onset) and influenza vaccination history for the 
2015/16 season including date of vaccination and route 
of administration (intranasal/injection). In England, 
residence in an area where a primary school LAIV immu-
nisation programme took place was also recorded.
A further specific sub-analysis was undertaken among 
children two to 17 years of age for the period 1 October 
2013 until 1 May 2016. This covered the period since 
the introduction of LAIV in the UK. All aspects of data 
collection, testing and analysis were comparable over 
this period and are as described above.
Laboratory methods
Sentinel GP surveillance networks sent the respira-
tory samples to the national laboratories as previously 
outlined [7]. Laboratory confirmation was made using 
comparable real-time PCR methods able to detect 
circulating influenza A and B viruses [8,9]. Positive 
samples were sent to the reference laboratories for 
genetic characterisation. Isolation of influenza viruses 
was tried from all PCR-positive samples using Madin-
Darby canine kidney epithelial (MDCK) cells or MDCK 
cells containing the cDNA of human 2,6-sialtransferase 
(SIAT1) cells as described previously [10,11].
Antigenic characterisation was only undertaken at the 
PHE reference laboratory. Post-infection ferret antisera 
were used in haemagglutination inhibition (HI) assays 
with turkey red blood cells to antigenically character-
ise influenza A(H1N1)pdm09 and influenza B virus iso-
lates with a haemagglutination titre ≥ 40 [12]. Reference 
virus strains used for HI assays for A(H1N1)pdm09 
Figure 1
Specimen inclusion and exclusion criteria, end-of-season 
2015/16 influenza vaccine effectiveness evaluation, United 
Kingdom, 1 October 2015–1 May 2016 (n = 5,811)
N=5,811 
in original dataset
Samples included in the analysis
N=3,841
Cases 
N=1,155
Controls 
N=2,686
Sequentially excluded samples:
1. Date of sample prior to 1 October 2015 (n=113)
2. Live attenuated influenza vaccine strain (n=1)
3. Vaccination status unknown  (n=194)
4. Vaccination less than 14 days from onset (n=101)
5. Date of onset unknown (n=242)
6. Swab more than seven days after onset (n=1,319)
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Figure 2
Phylogenetic tree of the haemagglutinin genes of sentinel influenza B isolates, United Kingdom, October 2015–May 2016 
(n = 324)
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viruses included A/California/7/2009 (vaccine strain) 
grown in embryonated chicken eggs and other A(H1N1)
pdm09 England strains grown in embryonated chicken 
eggs or tissue culture cells. Reference virus strains 
used for HI assays for influenza B viruses included B/
Phuket/3073/2013 (trivalent and quadrivalent vaccine 
strain) and B/Brisbane/60/2008 (quadrivalent vaccine 
strain) together with a panel of other egg- and tissue 
culture-grown influenza B viruses from both the B/
Yamagata/16/88-lineage and the B/Victoria/2/87 line-
age. The fold difference between the homologous HI 
titre for the corresponding vaccine strain and the HI 
titre for each clinical isolate was calculated to deter-
mine antigenic similarity of clinical isolates to the vac-
cine strain.
Nucleotide sequencing of the haemagglutinin (HA) 
gene was undertaken (primer sequences available on 
request) for a subset of influenza A(H1N1)pdm09 and 
B viruses selected to be representative of the range of 
the patients’ age, date of sample collection, geographi-
cal location and, if performed, antigenic characterisa-
tion of the virus isolate, and phylogenetic trees were 
constructed with a neighbour-joining algorithm avail-
able in the Mega 6 software (http://www.megasoft-
ware.net) [13]. The A(H1N1)pdm09 results have been 
previously presented [5]. HA sequences from reference 
strains used in the phylogenetic analysis for influ-
enza B in this paper were obtained from GenBank: 
B/Malaysia/2506/2004 (CY038287), B/Jilin/20/2003 
(CY033828), B/Yamagata/16/88 (CY018765), B/
Victoria/2/87 (M58428), B/HongKong/330/2001 
(AF532549) and from the EpiFlu database of the Global 
Table 1
Influenza B haemagglutinin sequences obtained from GISAID used in the phylogenetic analysis
Influenza virus isolate
Segment ID/
Accession 
number
Country
Collection 
date (year-
month-day)
Originating laboratory Submitting laboratory
B/Brisbane/3/2007 EPI154537 Australia 2007-Jan-01
Queensland Health 
Scientific Services, 
Queensland, Australia
WHO Collaborating 
Centre for Reference and 
Research on Influenza, 
Victoria, Australia
B/Stockholm/12/2011 EPI346827 Sweden 2011-Mar-28
Swedish Institute for 
Infectious Disease 
Control, Solna, Sweden
National Institute for 
Medical Research, London, 
UK
B/England/515/2014 EPI555201
United 
Kingdom 2014-Oct-22
Public Health England, 
London, UK
National Institute for 
Medical Research, London, 
UK
B/Estonia/77391/2013 EPI467120 Estonia 2013-Apr-08
Health Protection 
Inspectorate, Tallin, 
Estonia
National Institute for 
Medical Research, London, 
UK
B/Odessa/3886/2010 EPI271913 Ukraine 2010-Mar-19 Ministry of Health of Ukraine, Kiev, Ukraine
National Institute for 
Medical Research, London, 
UK
B/Phuket/3073/2013 EPI540675 Australia 2013-Nov-21
WHO Collaborating 
Centre for Reference and 
Research on Influenza, 
Victoria, Australia
National Institute for 
Medical Research, London, 
UK
B/Massachusetts/02/2012 EPI438406 United States 2012-Jan-01 New York Medical College, New York, US
Centers for Disease 
Control and Prevention, 
Atlanta, US
B/Wisconsin/01/2010 EPI271545 United States 2010-Feb-20
Wisconsin State 
Laboratory of Hygiene, 
Madison, US
Centers for Disease 
Control and Prevention, 
Atlanta, US
B/Hawaii/02/2010 EPI271558 United States 2010-Mar-25
State of Hawaii 
Department of Health, 
Pearl City, US
Centers for Disease 
Control and Prevention, 
Atlanta, US
B/Brisbane/60/2008 EPI172555 Australia 2008-Aug-04
Centers for Disease 
Control and Prevention, 
Atlanta, US
B/Florida/4/2006 EPI134356 United States 2006-Nov-01
Centers for Disease 
Control and Prevention, 
Atlanta, US
B/Bangladesh/3333/2007 EPI156050 Bangladesh 2007-Aug-18
Centers for Disease 
Control and Prevention, 
Atlanta, US
GISAID: Global Initiative on Sharing All Influenza Data; UK: United Kingdom; US: United States; WHO: World Health Organization.
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Initiative on Sharing All Influenza Data (GISAID) (Table 
1).
Statistical methods
Patients were defined as vaccinated if they had 
received the 2015/16 seasonal vaccine at least 14 
days before first onset of ILI. Patients were excluded 
if they were vaccinated less than 14 days before symp-
tom onset. If vaccinated, but date of vaccination was 
unknown, the median date of vaccination of those with 
known dates was taken instead. Patients with date of 
onset not known or onset more than seven days before 
swabbing were also excluded. A similar approach was 
used to undertake a pooled analysis for the 2013/14, 
2014/15 and 2015/16 seasons.
The odds ratios (OR) obtained from multivariable 
logistic regression models were used to calculate VE 
with influenza laboratory results as the outcome and 
influenza vaccination status as the linear predictor. 
Influenza A(H1N1)pdm09- and influenza B-specific VE 
was also calculated. Samples positive for other sub-
types were excluded as the numbers were too small, 
except for the three-season pooled analysis, which 
also included influenza A(H3N2). The adjusted esti-
mates were set based on past seasons as age (age 
groups: 0–4, 5–17, 18–44, 45–64, ≥ 65 years), month of 
sample collection, residence in area where a primary 
school programme was in place, sex and surveillance 
scheme. We also explored whether being in a risk 
group for whom vaccination is recommended provided 
any evidence of confounding. For the three-year pooled 
analysis, year was also included in the model. All sta-
tistical analyses were carried out in Stata version 13 
(StataCorp, College Station, Texas).
The HA sequences from England obtained in this study, 
which were also used in the phylogenetic analysis, 
were deposited in GISAID under the following accession 
numbers: EPI679258, EPI811543, EPI811551, EPI811554, 
EPI811562, EPI811570, EPI811578, EPI811586, EPI811594, 
EPI811598, EPI811606, EPI811614, EPI811622, 
EPI811626, EPI811629, EPI811637, EPI811645, 
EPI811648, EPI811656, EPI811664, EPI811671, 
EPI811675, EPI811683, EPI811691, EPI811699, 
EPI811707, EPI811715, EPI811723, EPI811726, EPI811734, 
EPI811742, EPI811750, EPI811758, EPI811766, EPI811774, 
EPI811782, EPI811788, EPI811796, EPI811799, 
EPI811807, EPI811815, EPI811823, EPI811831, EPI811839, 
EPI811842, EPI811845, EPI811853, EPI811856, 
EPI811864, EPI811868, EPI811876, EPI811884, 
EPI811891, EPI811894, EPI811898, EPI811906, 
EPI811909, EPI811915, EPI811916, EPI811924, EPI811932, 
EPI811940, EPI811944, EPI811952, EPI811958.
Results
Of the 5,811 swabbed individuals potentially eligible, 
3,841 individuals were confirmed eligible and included 
in the study (Figure 1). The details of those included 
in the study are provided by swab result in Table 2, 
including those with missing data. There were a total 
of 2,686 controls, 351 (9.1%) influenza B detections, 
770 A(H1N1)pdm09 detections (20.0%), 24 influenza 
A(H3N2) detections (0.6%) and 15 influenza A(untyped) 
detections (0.4%). Four samples tested positive for 
both A(H1N1)pdm09 and influenza B and one sample 
was positive for both A(H1N1)pdm09 and A(H3N2). 
Positivity rates differed significantly by age group, sex, 
risk group, month, scheme, vaccination status and 
area of primary school programme in England (Table 2).
Influenza A(H1N1)pdm09 and B strain 
characterisation from sentinel samples
Since week 40 in 2015, a total of 730 influenza viruses 
from this study have been characterised by the PHE 
Respiratory Virus Unit and the West of Scotland 
Virology Centre: 128 antigenically, 293 genetically and 
309 through both methods. Only the PHE Respiratory 
Virus Unit undertook the antigenic analysis.
A total of 482 influenza A(H1N1)pdm09 viruses were 
characterised. All belonged in the genetic subgroup 
6B, which had been the predominant genetic subgroup 
in the 2014/15 season. Some heterogeneity was seen in 
the HA of the current season’s A(H1N1)pdm09 viruses, 
with some newly emerging genetic subgroups: the HA 
genes of the majority (93%) of A(H1N1)pdm09 viruses 
fell into genetic cluster 6B.1, characterised by the amino 
acid changes S84N, S162N (with gain of a potential gly-
cosylation site) and I216T, with a subset in this cluster 
having the substitution A215G. Less than 6% of viruses 
fell into a second emerging cluster (6B.2) and had the 
amino acid substitutions V152T, V173I, E491G and D501E 
in the HA gene, or into a third minor cluster with sub-
stitutions N129D, R450K and E491G. A few viruses from 
this season did not have any of these changes or had 
only the substitution S84N, and clustered with A(H1N1)
pdm09 viruses from season 2014/15 (6B subgroup). 
A tree showing the phylogenetic relationships for the 
A(H1N1)pdm09 has already been published [5]. Of 123 
A(H1N1)pdm09 viruses isolated from sentinel samples 
between December 2015 and April 2016 and analysed 
by HI assay using an extended panel of ferret post-
infection sera including a ferret post-infection antise-
rum to A/California/7/2009 (NIBSC, UK), 100% were 
antigenically similar to the A/California/7/2009 north-
ern hemisphere 2015/16 A(H1N1)pdm09 vaccine strain. 
Using this extended panel of ferret post-infection anti-
sera, no antigenic low reactors to A/California/7/2009 
antisera were observed.
A total of 324 influenza B viruses were characterised: 
more than 96% of them belonged to the B/Victoria lin-
eage in clade 1A, represented by B/Brisbane/60/2008 
(the 2015/16 quadrivalent vaccine strain) (Figure 2). 
Viruses in this clade have N75K, N165K and S172P in 
their HA compared with the previous vaccine virus. 
Additional amino acid substitutions seen this season 
were I117V, N129D and V146I. A few (< 3%) UK 2015/16 
B/Yamagata lineage viruses were detected, all belong-
ing to genetic clade 3, with amino acid substitutions 
S150I, N165Y and G229D relative to a previous vaccine 
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Table 2
Controls Influenza Ba Influenza A(H1N1)a
Influenza 
A(H3N2)
Influenza 
A(untyped) Total
a p valueb
Age group (years) 
0–4 273 71.3 19 5.0 91 23.8 1 0.3 1 0.3 383
< 0.0001
5–17 392 69.3 92 16.3 78 13.8 5 0.9 1 0.2 566
18–44 1,022 65.9 170 11.0 348 22.4 7 0.5 5 0.3 1,551
45–64 636 70.0 47 5.2 211 23.2 7 0.8 7 0.8 908
≥ 65 346 84.6 19 4.6 39 9.5 4 1.0 1 0.2 409
Missing 17 70.8 4 16.7 3 12.5 0 0 0 0 24
Sex 
Female 1,627 72.4 188 8.4 417 18.5 12 0.5 8 0.4 2,248
< 0.0001Male 1,046 66.4 162 10.3 350 22.2 12 0.8 7 0.4 1,576
Missing 13 76.5 1 5.9 3 17.6 0 0 0 0 17
Surveillance scheme 
Northern Ireland 76 49.0 22 14.2 51 32.9 0 0 6 3.9 155
< 0.0001
RCGP 1,148 64.0 179 10.0 449 25.0 19 1.1 0 0 1,793
SMN 138 67.0 12 5.8 50 24.3 1 0.5 5 2.4 206
Scotland 1,242 81.8 101 6.6 172 11.3 3 0.2 4 0.3 1,519
Wales 82 48.8 37 22.0 48 28.6 1 0.6 0 0 168
Risk group 
No 1,794 66.5 276 10.2 607 22.5 14 0.5 9 0.3 2,697
< 0.0001Yes 817 79.7 53 5.2 141 13.8 9 0.9 6 0.6 1,025
Missing 75 63.0 22 18.5 22 18.5 1 0.8 0 0 119
Interval onset–sample (days) 
0–1 292 67.6 41 9.5 95 22.0 2 0.5 2 0.5 432
< 0.00012–4 1,351 66.1 216 10.6 463 22.6 14 0.7 5 0.2 2,045
5–7 1,043 76.5 94 6.9 212 15.5 8 0.6 8 0.6 1,364
Month 
October 304 98.7 1 0.3 1 0.3 1 0.3 1 0.3 308
< 0.0001
November 396 96.1 6 1.5 8 1.9 2 0.5 0 0 412
December 463 86.4 5 0.9 67 12.5 0 0 1 0.2 536
January 541 68.7 26 3.3 217 27.6 3 0.4 2 0.3 787
February 445 56.1 67 8.4 275 34.7 4 0.5 3 0.4 793
March 366 48.0 197 25.8 190 24.9 7 0.9 5 0.7 763
April 171 70.7 49 20.2 12 5.0 7 2.9 3 1.2 242
Vaccination status (all ages) 
Unvaccinated 1,959 66.4 308 10.4 658 22.3 15 0.5 13 0.4 2,949
< 0.0001Vaccinated (14–91 days ago) 377 89.8 6 1.4 33 7.9 3 0.7 1 0.2 420
Vaccinated (>91 days ago) 350 74.2 37 7.8 79 16.7 6 1.3 1 0.2 472
Pilot area (SMN and RCGP only) 
No 1,185 63.8 181 9.7 470 25.3 20 1.1 2 0.1 1,858
0.057Yes 91 72.2 9 7.1 24 19.0 0 0 2 1.6 126
Missing 11 64.7 1 5.9 4 23.5 0 0 1 5.9 17
Vaccine status (by route) (2–17 years) 
Not vaccinated 402 65.5 94 15.5 112 18.2 6 1.0 1 0.2 614
0.01
Injection 16 84.2 3 15.8 0 0 0 0 0 0 19
Intranasal 89 77.4 4 3.5 22 19.1 0 0 0 0 115
Missing 12 70.6 1 5.9 4 23.5 0 0 0 0 17
RCGP: Royal College of General Practitioners Research and Surveillance Centre; SMN: Specialist Microbiology Network.
Note: Differences between cases and controls for all variables in this table were statistically significant.
a Four positive for influenza A(H1N1) and B; one positive for influenza A(H1N1) and A(H3N2). Duplicates are not included in row totals. 
b Positive vs negative for influenza.
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strain. More recent substitutions observed this season 
included N116K, K298E, E312K and also L172Q seen in 
the majority of B/Yamagata clade 3 viruses.
Of 99 influenza B viruses isolated from sentinel sources 
between December 2015 and May 2016 and analysed by 
HI assay, 98 (99%) were characterised as belonging to 
the B/Victoria/2/87 lineage and were antigenically sim-
ilar to B/Brisbane/60/2008, the influenza B/Victoria-
lineage component of the 2015/16 northern hemisphere 
quadrivalent vaccines. One virus (1%) was character-
ised as belonging to the B/Yamagata/16/88-lineage 
and was antigenically similar to B/Phuket/3073/2013, 
the influenza B/Yamagata-lineage component of the 
2015/16 northern hemisphere trivalent and quadriva-
lent vaccines.
Model fitting for vaccine effectiveness 
estimation
The variables incorporated in the multivariable model 
(month of sample collection, age group, sex, surveil-
lance scheme and primary school programme area) 
were all significantly associated with swab positivity, 
and all except primary school programme area and 
sex were confounders for the vaccine effects (changed 
estimates by more than 5%). As with previous seasons’ 
analyses [5-7], risk group was not included in the final 
model as it was not a confounder and data were miss-
ing for 119 samples (3.1%).
The crude and adjusted VE estimates against all con-
firmed influenza, influenza A(H1N1)pdm09 and influ-
enza B for the 2015/16 season are given in Table 3. 
There were inadequate numbers to estimate VE against 
influenza A(H3N2). The adjusted VE was 52.4% (95% 
confidence interval (CI): 41.0–61.6) against all labora-
tory-confirmed influenza for all ages.
Table 3 shows that the adjusted VE was 54.5% (95% 
CI: 41.6–64.5) against influenza A(H1N1)pdm09 and 
specifically 48.9% (95% CI: 26.4–64.5) for clade 6B1 
viruses. The age-specific VE against influenza A(H1N1)
pdm09 ranged from 48.5% (95% CI: 8.5–71.0) in those 
aged two to 17 years to 59.8% (95% CI: 35.8–74.8) 
in those aged 18 to 44 years (Table 4). There was no 
significant difference in VE against influenza A(H1N1)
pdm09 by time since vaccination or period of vaccina-
tion (Table 4), overall or by age (adult/child).
Table 3 also shows that the adjusted VE was 54.2% 
(95% CI: 33.1–68.6) against influenza B and specifically 
57.3% (95% CI: 28.4–74.6) for viruses of the B/Victoria 
lineage. The age-specific VE against influenza B ranged 
from 76.5% (95% CI: 41.9–90.5) in those aged two to 
17 years to −20.0% (95% CI: −259.1 to 59.8) in those 
aged 65 years and older (Table 4), although these age-
specific differences in VE were not significant. There 
was no significant difference in influenza B VE by time 
since vaccination or by period of vaccination (Table 4).
The VE results by type of vaccine in children two to 17 
years of age are given in Table 5. For children receiving 
LAIV, the overall VE against all laboratory-confirmed 
influenza was 57.6% (95% CI: 25.1–76) and specifically 
81.4% (95% CI: 39.6–94.3) for influenza B and 41.5% 
(95% CI: −8.5 to 68.5) for influenza A(H1N1)pdm09. This 
compares to an overall VE of 77.8% (95% CI: 7.3–94.7) 
for children receiving IIV and a specific VE of 56.3% 
(95%CI: −121.6 to 91.4) against influenza B and 100% 
(95%CI: 13.3–100) against influenza A(H1N1)pdm09. By 
age group, overall LAIV VE in two to eight year-olds was 
Table 3
Samples positive (cases; n = 1,155) and negative (controls; n = 2,686) for influenza A and B according to vaccination status 
and vaccine effectiveness estimates, United Kingdom, October 2015–May 2016
Cases Controls Crude VE 
(95% CI)
Adjusteda VE 
(95% CI)Vaccinated Unvaccinated Vaccinated Unvaccinated
Influenza A or B 165 990 727 1,959 55.1 (45.9–62.7)
52.4 
(41.0–61.6)
Influenza A(H1N1) 112 658 727 1,959 54.1 (43–63.1)
54.5 
(41.6–64.5)
Influenza A/6B1b 45 232 651 1,739 48.2 (28.8–62.8)
48.9 
(26.4–64.5)
Influenza B 43 308 727 1,959 62.4 (47.7–73.0)
54.2 
(33.1–68.6)
Influenza B/
Victoriab 21 161 651 1,739
65.2 
(44.6–78.1)
57.3 
(28.4–74.6)
CI: confidence interval; RCGP: Royal College of General Practitioners Research and Surveillance Centre; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, pilot area and surveillance scheme.
b Based only on data from RCGP and Scotland only.
Table 3 shows that the adjusted VE was 54.5% (95% CI: 41.6–64.5) against influenza A(H1N1)pdm09 and specifically 48.9% (95% CI: 26.4–
64.5) for clade 6B1 viruses. The age-specific VE against influenza A(H1N1)pdm09 ranged from 48.5% (95% CI: 8.5–71.0) in those aged two to 17 
years to 59.8% (95% CI: 35.8–74.8) in those aged 18 to 44 years (Table 4). There was no significant difference in VE against influenza A(H1N1)
pdm09 by time since vaccination or period of vaccination (Table 4), overall or by age (adult/child).
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50.2% (95% CI: 1.6–74.8) and 63.9% (95% CI: −20.3 to 
89.2) in nine to 17 year olds.
In 2013/14, the dominant circulating strain was influ-
enza A(H1N1)pdm09, whereas in 2014/15, the domi-
nant circulating strain was influenza A(H3N2), which 
had antigenically and genetically drifted from the vac-
cine strain, followed by influenza B mainly of the B/
Yamagata lineage. Over the three seasons, the overall 
VE of LAIV was 53.1% (95% CI: 31.4–67.9) against all 
confirmed influenza, with a VE of 31.5% (95%CI: −50.4–
68.8) for IIV (Table 6). The LAIV VE showed evidence of 
significant VE against laboratory-confirmed influenza 
B infection, borderline significance against influenza 
A(H3N2) and moderate, non-significant effectiveness 
against influenza A(H1N1)pdm09. Over the three-year 
period, albeit with small numbers, there was no evi-
dence of significant effectiveness of IIV against influ-
enza B or A(H3N2), but effectiveness of 100% (95% CI: 
16.2–100) against influenza A(H1N1)pdm09.
Discussion
In the 2015/16 season, the UK completed the third sea-
son of the introduction of a universal paediatric LAIV 
programme. The 2015/16 season was characterised by 
late, prolonged influenza A(H1N1)pdm09 activity, with 
predominance of an emerging genetic HA subgroup, 
which was antigenically well matched to the vaccine 
strain, followed by circulation of influenza B viruses, 
predominantly of the B/Victoria lineage which was not 
represented in the 2015/16 trivalent inactivated influ-
enza vaccine. The end-of-season VE was moderately 
good in adults for influenza A(H1N1)pdm09 and in 
adults younger than 65 years for influenza B, despite 
the B lineage mismatch for the trivalent influenza vac-
cine, the main vaccine used in adults. Overall VE for 
LAIV in children was also moderately good and specifi-
cally for influenza B, it was very good, although protec-
tion was less against influenza A(H1N1)pdm09. There 
was no evidence to suggest waning vaccine-derived 
protection or changes in circulating strains over the 
2015/16 season.
We found an overall significant VE of 52.4% and spe-
cifically of 54.5% against influenza A(H1N1)pdm09, 
the dominant circulating strain this season. Although 
2015/16 has seen the continued emergence of the new 
genetic subgroups 6B.1 and 6B.2, the antigenic char-
acterisation indicates a good match to the 2015/16 
influenza vaccine strain and no measurable differences 
between these two emerging groups, which reinforces 
the VE findings in this paper. These levels of effective-
ness are consistent with those reported mid-season 
in 2015/16 [5], but also in earlier A(H1N1)pdm09 sea-
sons, in particular in 2010/11 [14]. The 2015/16 A(H1N1)
pdm09 VE results were also similar to the mid-season 
estimates reported from North America and elsewhere 
in Europe this season [15,16]. The continuing apparent 
antigenic and epidemiological match to the vaccine 
strain remains encouraging and supports the World 
Health Organization’s recommendation that the vac-
cine for the 2016/17 northern hemisphere winter should 
include an A/California/7/2009-like vaccine strain [17].
In younger adults under 65 years of age, influenza B 
VE was over 50%. Almost all vaccinated adults in the 
UK can be expected to have received the 2015/16 tri-
valent inactivated (rather than the quadrivalent) influ-
enza vaccine, which contained the B/Yamagata vaccine 
strain in 2015/16. Our results indicate that despite this 
lineage mismatch, the 2015/16 IIV in younger adults 
continued to provide important levels of protection 
against influenza B, findings which are consistent with 
earlier published literature [18]. On the other hand, we 
failed to find evidence of significant VE against influ-
enza B in the elderly, although underpowered with only 
19 positive detections and a low positivity of 4.6% in 
this age group. This is in contrast to the 2014/15 sea-
son, when influenza vaccines elsewhere in Europe 
provided effectiveness of 50.4% (95% CI: 14.6–71.2) 
against influenza B in those older than 65 years [19]; 
in that season, the dominant circulating strain was B/
Yamagata and belonged to a clade that was antigeni-
cally similar to the vaccine virus that season. Evidence 
of cross-protection, as we seem to have seen in the 
younger adults this season, might have important 
implications for the potential incremental cost-effec-
tiveness and recommendations for preferential use 
of quadrivalent vaccines in adults and highlights the 
importance of gathering further data in this area to bet-
ter inform such decisions.
Table 4
Adjusted vaccine effectiveness estimates for influenza 
by age, time since vaccination, vaccination period and 
risk group, United Kingdom, October 2015–May 2016 
(n = 3,841)
Factor Level
Adjusted VEa by type 
% (95% CI)
A + B A(H1N1)pdm09 B
Age (years)b
2–17 60.6 (34.4–76.3)
48.5 
(8.5–71.0)
76.5 
(41.9–90.5)
18–44 55.3 (34.2–69.6)
59.8 
(35.8–74.8)
45.9 
(1.0–70.4)
45–64 55.4 (34.6–69.5)
58.6 
(36.9–72.8)
65.0 
(15.1–85.6)
≥ 65 29.1 (−34.1 to 61.8)
56.1 
(7.2–79.3)
-20.2 
(−259.1 to 59.8)
Period of 
vaccinationb
Oct - Jan 50.0 (27.6–65.4)
54.3 
(31.6–69.4)
35.9 
(−70.5 to 75.9)
Feb - April 53.0 (38.7–64.0)
53.6 
(36.1–66.3)
56.9 
(35.1–71.3)
Time from 
vaccination 
to onsetb
< 3 months 51.4 (29.9–66.3)
56.7 
(34.9–71.3)
53.1 
(−12.1 to 80.3)
> 3 months 52.7 (39.2–63.2)
53.9 
(38.1–65.6)
53.4 
(30.0–69.0)
CI: confidence interval; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, pilot area and surveillance scheme.
b No significant evidence of interaction.
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 Among children two to 17 years of age, we observed 
an overall significant VE of 57.6% for the quadrivalent 
LAIV vaccine this season, specifically 81.4% for influ-
enza B and 41.5% for influenza A(H1N1)pdm09, with a 
similar picture when examining the previous three sea-
sons. Over the three seasons, the overall effectiveness 
of LAIV was higher compared with inactivated vaccine 
in that age group, specifically for influenza A(H3N2) 
and B, but lower in 2015/16 and specifically for influ-
enza A(H1N1)pdm09. These findings are in contrast to 
those recently reported by the US CDC who found an 
overall VE of only 3% for LAIV in two to 17 year-old chil-
dren with very low VE against influenza A(H1N1)pdm09, 
while the inactivated vaccine showed significant effec-
tiveness [3]. The US first noted lower VE of LAIV against 
influenza A(H1N1)pdm09 in 2013/14, which on further 
investigation was considered related to reduced ther-
mostability of the A/California/7/2009 vaccine strain 
[20]. This led to the replacement of the A(H1N1)pdm09 
LAIV vaccine strain with the more recently emerged A/
Bolivia/559/2013 vaccine strain for the 2015/16 season. 
Based on the 2015/16 VE findings from the CDC, the US 
Advisory Committee on Immunisation recommended 
a temporary suspension of use of LAIV for children in 
the US for the forthcoming 2016/17 season [3]. In addi-
tion to the UK findings presented here, Finland, in its 
first season of use of LAIV in pre-school age children, 
found overall levels of protection of 51%, similar to the 
UK [21]. 
The reasons why the observed levels of overall pro-
tection were higher in Europe than in the US, with 
apparent reduced protection against influenza A(H1N1)
pdm09 compared to IIV, remain under investigation. 
Several hypotheses have been suggested. Firstly, are 
the observed differences real or the consequence of 
a methodological difference? If real, viral interference 
between the A(H1N1)pdm09 vaccine strain and the 
other influenza vaccine viruses in the quadrivalent 
LAIV vaccine might provide an explanation; such inter-
ference has been discussed previously [22] and might 
be reinforced by prior vaccination with LAIV and/or IIV 
in young children (which is at present much more likely 
in North America than Europe) or by repeat vaccination 
in-season, with the US offering two doses of influenza 
vaccine to children compared with one dose for healthy 
children in Europe. A further explanation is possible 
antigenic drift between the A/Bolivia/559/2013 vac-
cine strain in the 2015/16 LAIV vaccine and circulating 
A(H1N1)pdm09 strains in winter 2015/16, although anti-
genically, the virus is considered to be well matched. 
Finally, programmatic or logistical differences, e.g. 
related to cold chain or vaccine handling might play a 
role. 
Further work is required to investigate these hypoth-
eses, although UK programme evaluation results from 
2013/14 and 2014/15 already suggest that the UK LAIV 
paediatric programme reduced influenza circulation 
when comparing pilot areas where children of pri-
mary school age were offered vaccine to those areas 
where they were not [23,24]. The UK VE results pre-
sented in this paper have been reviewed by the JCVI 
who strongly recommended not to change the current 
influenza immunisation strategy planned for 2016/17, 
but further work is required to better understand these 
recent observations in the light of the US findings and 
to potentially optimise vaccine composition.
Although waning protection post vaccination has 
recently been noted [25] and although 2015/16 was 
a particularly late influenza season with significant 
activity until late into the spring, there was no evi-
dence to suggest either waning protection by time since 
Table 5
Vaccine effectiveness estimates for influenza by type of vaccine in two to 17 year-olds, United Kingdom, October 2015–May 
2016 (n = 729)
Type/subtype Type of vaccine
Cases 
(unvaccinated; 
vaccinated)
Controls 
(unvaccinated; 
vaccinated)
Crude VE 
(95% CI)
Adjusted VEa 
(95% CI)
All
Intranasal 212; 26 402; 89 44.6 (11.6–65.3)
57.6 
(25.1–76)
Injectable 212; 3 402; 16 64.4 (−23.4 to 89.8)
77.8 
(7.3–94.7)
Influenza A/(H1N1)pdm09
Intranasal 112; 22 402; 89 11.3 (−47.9 to 46.8)
41.5 
(−8.5 to 68.5)
Injectable 112; 0 402; 16 100 (13.3–100)
100 
(13.3–100)b
Influenza B
Intranasal 95; 4 402; 89 81 (46.9–93.2)
81.4 
(39.7–94.3)
Injectable 95; 3 402; 16 20.7 (−177.8 to 77.3)
56.3 
(−121.6 to 91.4)
CI: confidence interval; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, pilot area and surveillance scheme.
b Cornfield’s unadjusted estimate.
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vaccination or changes in effectiveness by vaccination 
period due to the emergence of new clades or lineages 
over the course of the season in the UK. Our findings 
are congruent with recent work which suggests that 
intra-seasonal waning is of lesser importance with 
influenza A(H1N1)pdm09 and influenza B compared 
with influenza A(H3N2) [25].
The paper has a number of strengths. It uses a well-
established methodology, the TNCC, the results of 
which approximate well to more traditional case–con-
trol approaches [26]. Data completeness was very high 
and the integration of genetic characterisation data 
has allowed the estimation of clade- and lineage-spe-
cific VE. Caution is needed in the interpretation of the 
results in children two to 17 years of age owing to the 
small sample size, particularly in relation to IIV where 
only a small proportion of the paediatric control popu-
lation with available information (16/507, 3%) were 
reported to be vaccinated, while for LAIV, 18% of con-
trols were reported vaccinated.
Conclusion
In summary, notwithstanding the limitation of the 
small sample size, our findings together with those 
from Finland confirm encouraging overall levels of pro-
tection for LAIV. This protection is particularly effec-
tive against influenza B, though less against influenza 
A(H1N1)pdm09, a finding which in the light of observa-
tions in the US requires further investigation.
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(−274.8 to 60.3)
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